Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 72, Issue 3, 2006, Pages 265-270

  Kabadi, Udaya M ^a,b,c   Kabadi, Mary ^a  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Glimepiride; Metformin; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN ASPART; METFORMIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DOSE RESPONSE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CHEMOTHERAPY, ADJUVANT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PLACEBOS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 33646554847     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.10.024     Document Type: Article

References (38)

1. Riddle M., Hart J.S., Bouma D.J., Phillipson B.E., and Youker G. Efficacy of bedtime NPH insulin in treatment of secondary failure to glibenclamide. Diabetes Care 12 (1989) 582-585
2. Sontaniemi E. Insulin and sulfonylurea in the therapy of type 2 diabetes. Diabetes Res. Clin. Pract. 8 (1990) 243-251
3. Simpson H., Sturley R., Stirling C., and Reckless J. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic subjects. Diabetes Med. 7 (1990) 143-147
4. Del Prato S., Vigili de Kreutzenberg S., Riccio A., Maifreni L., Duner E., Lisato G., et al. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic subjects with secondary failure to oral agents. Diabetologia 33 (1990) 688-695
5. Groop L., and Widen E. Treatment strategies for secondary sulfonylurea failure. Diabetes Metab. 17 (1991) 219-223
6. Kabadi U., and Kabadi M. Type II diabetic subjects with secondary failure: treatment with pre-breakfast mixed ultralente and regular insulin with a sulfonylurea. J. Fam. Pract. 33 (1991) 349-353
7. Yki-Jarvinen H., Kauppila M., Kujansuue E., Lahti J., Marjanen T., Niskanen L., et al. Comparison of insulin regimens in subjects with non-insulin dependent diabetes mellitus. N. Engl. J. Med. 329 (1992) 1426-1433
8. Johnson J.L., Wolf S.L., and Kabadi U.M. Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes mellitus. Arch. Intern. Med. 156 (1996) 259-264
9. Lindstrom T., Nystrom F.H., Olsson A.G., and Arnqvist H.J. The lipoprotein differs during insulin treatment alone and combination therapy with insulin and sulfonylureas in subjects with type 2 diabetes mellitus. Diabetes Med. 16 (1999) 820-826
10. Wright A., Felix Burden A.C., Paisey R.B., Cull C.A., and Holman R.R. Sulfonylurea inadequacy. Diabetes Care 25 (2002) 330-336
11. Riddle M.C., and Schneider J. The glimepiride combination group. Beginning insulin treatment of obese subjects with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 21 (1998) 1052-1057
12. Schwartz S., Raskin P., Fonesca V., and Graveline J. Effect of troglitazone in insulin-treated subjects with type II diabetes mellitus. N. Engl. J. Med. 338 (1998) 861-866
13. Buse J.B., Gumbiner B., Mathias N.P., Nelson D.B., Faja B.W., and Whitcomb R.W. Troglitazone use in insulin-treated type 2 diabetic subjects. Diabetes 48 (1999) 1455-1461
14. Yu J.G., Kruszynska Y.T., Mulford M.I., and Olefsky J.M. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic subjects. Diabetes 48 (1999) 2414-2421
15. Golay A., Guillet-Dauphine N., Fendel A., Juge C., and Assal J.P. The insulin-sparing effect of metformin in insulin-treated diabetic subjects. Diabetes Metab. Rev. 11 (1995) S63-S67
16. Giugliano D., Quatraro A., Consoli G., Minei A., Ceriello A., De Rosa N., et al. Metformin for obese, insulin-treated diabetic subjects: improvement in glycemic control and reduction of metabolic risk factors. Eur. J. Clin. Pharmacol. 44 (1993) 107-112
17. Slama G. The insulin sparing effect of metformin in insulin-treated diabetic subjects. Diabetic Metab. 7 (1991) 241-243
18. Chaudhuri A., Tomar R., Moharty P., Szudzik E., Bandyopadhyay A., Arian M., et al. The combination of insulin and metformin in treatment of non-insulin dependent diabetes mellitus. Endocr. Pract. 4 (1998) 259-267
19. Kabadi U., and Kabadi M. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Ann. Pharmacolther. 37 (2003) 1572-1576
20. Raskin P., Rendell M., Riddle M.C., Dole J.F., Freed M.I., Rosenstock J., and Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24 (2001) 1226-1232
21. Rosenstock J., Einhor D., Hershon K., and Glazer N.B. Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy. Int. J. Clin. Pract. 56 (2002) 251-257
22. Yki-Jarvinen H., Ryysy L., Nikkila K., Tulokas T., Vanamo R., and Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 130 (1999) 389-396
23. Strowig S., Aviles M., and Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27 (2004) 1577-1583
24. Kabadi U.M., O'Connell K.M., Johnson J., and Kabadi M. The effect of recurrent practice at home on the acceptability of capillary blood glucose readings. Diabetes Care 17 (1994) 1110-1114
25. Massi-Benedetti M., Herz M., and Pfeiffer C. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm. Metab. Res. 28 (1996) 451-455
26. Draeger E. Clinical profile of glimepiride. Diabetes Res. Clin. Pract. 28 (1995) S139-S146
27. Gonzales J.U., and Butron C.D. Glimepiride its action on body weight and lipid profile in type II diabetes mellitus. Prospective clinical experiment in Latin-America. Tribuna Medica 84 (1999) 151-158
28. Holstien A., Plaschke A., and Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab. Res. Rev. 17 (2001) 467-473
29. Korytkowski M., Thomas A., Reid L., Tedesco M.B., Gooding W.E., and Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 25 (2002) 1607-1611
30. Kabadi U.M., and Kabadi M. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clin. Ther. 26 (2004) 63-69
31. Overkamp D., Volk A., Maerker E., Heide P.E., Wahl H.G., Rett K., and Haring H.U. Accute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care 25 (2002) 2065-2073
32. Janka H.U., Plewe G., Riddle M.C., Klieve-Frisch C., Schweitzer M.A., and Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial therapy for type 2 diabetes. Diabetes Care 28 (2005) 252-259
33. Standl E., Maxeiner S., Raptis S., Karimi-Anderesi Z., and Schweitzer M.A. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 28 (2005) 419-420
34. Raskin P., Allen E., Hollender P., Lewin A., Gabbay R.A., Hu P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
35. J.K. Malone, L.F. Kerr, B.N. Campaigne, R.A. Sachson, J.H. Holcombe, Lispro Mixture-Glargine Study Group. Combined Therapy with Insulin Lispro Mix 75/35 Plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clinical Ther. 26 (2004) 2034-2044.
36. A. Wright, A.C. Felix Burden, R.B. Paisley, C.A. Cull, R.R. Holman, U.K. Prospective Diabetes Study Group. Sulfonylurea Inadequacy; efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. prospective diabetes study, Diabetes Care 25 (2002) 330-336.
37. UK Prospective Diabetes Study (UKPDS) Group. Intenstive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 12 (352) (1998) 837-853.
38. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet 12 (352) (1998) 854-865.